Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

"Patients with metabolic-associated steatohepatitis (MASH) also showed higher LDH levels. LDH levels were positively linked ...

Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a ...

Liver biopsy and noninvasive markers should be used to stage and grade nonalcoholic steatohepatitis (NASH) in patients. Though liver biopsy remains the 'suboptimal' gold standard for diagnosis of ...

Nonalcoholic steatohepatitis (NASH ... With all the progress that has occurred, it is interesting that liver biopsy evaluation has retained an essential role in the clinical diagnosis of NASH ...

Fintel reports that on February 13, 2025, Scotiabank initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Sector ...

Fintel reports that on February 7, 2025, Citigroup initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Neutral ...

Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...

Drinking alcohol if you have a large belly or diabetes more than doubles the risk of serious liver damage, while having high blood pressure and drinking nearly doubles the risk, a new study found.

Discover a potential breakthrough in treating severe liver scarring with a safe and effective therapy, as revealed by a recent Cleveland Clinic-led study.

Feb. 6, 2025 — The research found that heavy drinkers with either diabetes, high blood pressure or a high waist circumference are as much as 2.4 times more likely to develop advanced liver ...